Advanced Search

Home > Journals > Minerva Ginecologica > Past Issues > Minerva Ginecologica 2007 October;59(5) > Minerva Ginecologica 2007 October;59(5):529-41



A Journal on Obstetrics and Gynecology

Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index

Frequency: Bi-Monthly

ISSN 0026-4784

Online ISSN 1827-1650


Minerva Ginecologica 2007 October;59(5):529-41


The use of hormone replacement therapy in patients after breast cancer

Mueck A. O. 1, Rabe T. 2, Kiesel L. 3, Strowitzki T. 2

1 University Women’s Hospitals of Tuebingen, Tuebingen, Germany
2 University Women’s Hospitals of Heidelberg, Heidelberg, Germany
3 University Women’s Hospitals of Muenster, Muenster, Germany

Four prospective randomized studies and at least 15 observational studies investigating hormone replacement therapy (HRT) after breast cancer are available. Only the Hormonal replacement therapy After Breast cancer: Is iT Safe (HABITS) study shows an increased risk of relapse. This is probably associated with the relatively high number of patients with HRT treatment after estrogen receptor-positive cancers as well as to the preferred use of estrogen/progestin combined preparations. As is generally known, the progestin component especially seems to be mainly responsible for the probability of increased diagnosis frequency of breast cancer. However, the patient samples in all studies investigating HRT after breast cancer are small. Therefore, HRT should only be used if alternatives, such as specific not contraindicated phytopreparations or serotonin reuptake inhibitors, are not working. This is primarily due to forensic reasons. According to medical criteria, the data for the alternatives seem to be even more sparse, since many important questions remain unanswered, such as side effects and risks, or also regarding interactions with adjuvant hormone therapy.

language: English


top of page